Nature Reviews Clinical Oncology - Table of Contents alert Volume 13 Issue 2

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS
February 2016 Volume 13 Number 2
Impact Factor 14.180 *	In this issue Research Highlights Year in Review Reviews Perspectives Also this month  Featured article: HPV-FASTER: broadening the scope for prevention of HPV-related cancer F. Xavier Bosch, Claudia Robles, Mireia Díaz, Marc Arbyn, Iacopo Baussano, Christine Clavel, Guglielmo Ronco, Joakim Dillner, Matti Lehtinen, Karl-Ulrich Petry, Mario Poljak, Susanne K. Kjaer, Chris J. L. M. Meijer, Suzanne M. Garland, Jorge Salmerón, Xavier Castellsagué, Laia Bruni, Silvia de Sanjosé & Jack Cuzick
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
ESO, CNIO and NRCO Conference on Familial Cancer May 19-20, 2016 Madrid, Spain The conference aims to present the advances in this field from a multidisciplinary point of view. Familial cancer has become an important challenge for oncologists, geneticists, molecular biologists, and other professionals, due to its implications not only at individual but also at the familial and social level. Click here for more information.
RESEARCH HIGHLIGHTS Top Haematological cancer: Targeted agents: efficacy RESONATEs better with fine tuning Published online: 31 December 2015 p63 | doi:10.1038/nrclinonc.2015.233 PDF CNS cancer: Breaking boundaries — IDH mutations in glioma Published online: 20 January 2016 p64 | doi:10.1038/nrclinonc.2016.3 PDF Lung cancer: Resolving resistance to ALK-targeted therapy p64 | doi:10.1038/nrclinonc.2016.8 PDF Haematological cancer: Ibrutinib paves way to a brighter future in MCL Published online: 31 December 2015 p65 | doi:10.1038/nrclinonc.2015.231 PDF Liver cancer: Treatment choice — size matters Published online: 15 December 2015 p66 | doi:10.1038/nrclinonc.2015.221 PDF Drug therapy: Cetuximab or cisplatin in HNSCC? Published online: 31 December 2015 p66 | doi:10.1038/nrclinonc.2015.235 PDF In the news: From ASH 2015 Published online: 20 January 2016 p66 | doi:10.1038/nrclinonc.2016.2 PDF IN BRIEF Haematological cancer: Specific clones proliferate after induction therapy | Lung cancer: Gene therapy can be safely delivered in mice | Breast cancer: Antipsychotic agent supresses metastatic TNBC | Haematological cancer: SCT ameliorates the effects of FLT3-ITD in AML PDF Clinical Oncology JOBS of the week Open Line, Assistant, Associate or Full Professor - Cancer Immunotherapy - Stanford Cancer Institute Stanford Cancer Institute Postdoctoral Fellowship Positions Cleveland Clinic Postdoctoral Position � Cancer Immunotherapy (In Vivo Research) German Cancer Research Center (DKFZ). Postdoctoral Positions in Cancer Bioengineering and Biology University of Minnesota Faculty Position in Urology Research Job Mayo Clinic More Science jobs from Clinical Oncology EVENT 2016 Scientific Conference - Engineering and Physical Sciences in Oncology 25.06.16 Boston, USA More science events from
YEAR IN REVIEW		Top
Breast cancer in 2015: Academic research sheds light on issues that matter to patients Martine J. Piccart & Isabelle Gingras Published online: 20 January 2016 p67 | doi:10.1038/nrclinonc.2015.236 In 2015, academic-led trials provided evidence for safe de-escalation of adjuvant treatment in early stage breast cancer and answered important questions related to adjuvant regional irradiation and optimal first-line chemotherapy in advanced-stage disease. Furthermore, the development of novel therapies and potential tools for treatment tailoring will offer new hope to patients with breast cancer. Full Text | PDF
Colorectal and gastric cancer in 2015: The development of new agents and molecular classifications Eric Van Cutsem & Michel Ducreux Published online: 15 December 2015 p69 | doi:10.1038/nrclinonc.2015.217 In a little over the past year, several clinical trials have evaluated new drugs in patients with metastatic colorectal cancer and gastric cancer. Furthermore, genomics studies that attempted to unravel the molecular characteristics of colorectal and gastric cancer were published in 2015. The results of these endeavours will influence clinical practice in 2016 and beyond. Full Text | PDF
Ovarian cancer in 2015: Insights into strategies for optimizing ovarian cancer care Robert L. Coleman Published online: 31 December 2015 p71 | doi:10.1038/nrclinonc.2015.225 Advances in key areas of research have enabled improved outcomes for patients diagnosed with ovarian cancer in the past three decades. In 2015, this trend was maintained with important progress in areas such as guideline compliance, design of targeted approaches and molecular profiling. Full Text | PDF
Metastatic prostate cancer in 2015: The new and the old that is new again Julie N. Graff & Tomasz M. Beer Published online: 31 December 2015 p73 | doi:10.1038/nrclinonc.2015.226 In 2015, published trials highlighted the remarkable efficacy of docetaxel combined with androgen-deprivation therapy in patients with newly diagnosed metastatic prostate cancer. Also in 2015, a large study revealing potential molecular targets for metastatic castration-resistant prostate cancer therapies was published, along with a study showing activity of PARP inhibition in patients harbouring mutations in genes governing DNA repair. Full Text | PDF
Lung cancer in 2015: Bypassing checkpoints, overcoming resistance, and honing in on new targets Egbert F. Smit & Paul Baas Published online: 31 December 2015 p75 | doi:10.1038/nrclinonc.2015.223 Lung-cancer treatment paradigms continue to advance as we exploit our growing understanding of the genetic basis of both tumorigenesis and therapy resistance. Moreover, ongoing developments with targeted therapies are improving patient outcomes, with two new drugs approved in 2015 for non-small-cell lung cancer and many others showing promise. Full Text | PDF
Melanoma in 2015: Immune-checkpoint blockade — durable cancer control Elizabeth I. Buchbinder & F. Stephen Hodi Published online: 20 January 2016 p77 | doi:10.1038/nrclinonc.2015.237 In 2015, advances in immunotherapy for metastatic melanoma have come to fruition, with phase III data supporting the combination of ipilimumab and nivolumab as first-line therapy. Understanding the mechanisms involved in an effective antitumour immune response are now key to further advances. Several studies published in 2015 have increased our understanding of the complex relationships that exist between our immune system and malignancy. Full Text | PDF
REVIEWS		Top
Allogeneic transplantation for CML in the TKI era: striking the right balance Andrew J. Innes, Dragana Milojkovic & Jane F. Apperley Published online: 17 November 2015 p79 | doi:10.1038/nrclinonc.2015.193 Haematopoetic stem-cell transplantation (HSCT), has been the standard-of-care for eligible patients with chronic myeloid leukaemia (CML) for several decades. The development of tyrosine kinase inhibitors (TKIs) 15 years ago revolutionized the treatment of CML. For some patients, however, allogeneic HSCT remains the best treatment option. The authors of this Review discuss the current status of HSCT as a therapeutic option for CML management. Abstract | Full Text | PDF
Cancer-treatment-induced neurotoxicity—focus on newer treatments Jacqueline B. Stone & Lisa M. DeAngelis Published online: 22 September 2015 p92 | doi:10.1038/nrclinonc.2015.152 Neurotoxicity caused by treatment is widely recognized in patients with cancer. This Review addresses the main neurotoxicities of cancer treatment with a focus on the newer therapeutics. Recognition of these patterns of toxicity is important because drug discontinuation or dose adjustment might prevent further neurological injury. Familiarity with the neurological syndromes associated with cancer treatments enables clinicians to use the appropriate treatment for the underlying malignancy while minimizing the risk of neurological damage, which might preserve patient quality of life. Abstract | Full Text | PDF
The changing landscape of phase I trials in oncology Kit Man Wong, Anna Capasso & S. Gail Eckhardt Published online: 10 November 2015 p106 | doi:10.1038/nrclinonc.2015.194 The improved understanding of the molecular mechanisms that drive tumorigenesis has led to the development of molecularly targeted agents (MTAs) that inhibit specific proteins or pathways. However, the rate of drug approvals remains disappointingly low in oncology. The authors of this Review discuss several aspects of phase I trials that are evolving in the MTA era in order to adapt to the changing nature of cancer therapies and to expedite their clinical translation. Abstract | Full Text | PDF
PERSPECTIVES		Top
OPINION HPV-FASTER: broadening the scope for prevention of HPV-related cancer F. Xavier Bosch, Claudia Robles, Mireia Díaz, Marc Arbyn, Iacopo Baussano, Christine Clavel, Guglielmo Ronco, Joakim Dillner, Matti Lehtinen, Karl-Ulrich Petry, Mario Poljak, Susanne K. Kjaer, Chris J. L. M. Meijer, Suzanne M. Garland, Jorge Salmerón, Xavier Castellsagué, Laia Bruni, Silvia de Sanjosé & Jack Cuzick Published online: 01 September 2015 p119 | doi:10.1038/nrclinonc.2015.146 Human papillomavirus (HPV)-screening technologies and HPV vaccination are revolutionizing the management of cancers related to this virus, in particular, cervical neoplasms. At present, however, the effectiveness of these modalities is not optimal, owing to the limited scope of HPV-vaccination and cervical screening programmes. In this Perspectives, an international panel of experts describes for the first time a new campaign, termed 'HPV-FASTER', which aims to broaden the use of HPV vaccination coupled with HPV testing to women aged up to 30 years, and in some settings up to 50 years, with the aim of accelerating the reduction in the incidence of HPV infections and cervical cancer. The authors describe the evidence supporting this approach and details on how it might be implemented, discuss the opportunities—particularly in low-resource settings—and challenges associated with the strategy, and highlight key research gaps that need to be addressed in future studies. Abstract | Full Text | PDF
Erratum: Modern approaches to HLA-haploidentical blood or marrow transplantation. Christopher G. Kanakry, Ephraim J. Fuchs & Leo Luznik Published online: 31 December 2015 p132 | doi:10.1038/nrclinonc.2015.234 Full Text | PDF
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*Journal Citation Reports, Thomson, 2015. Nature Reviews Clinical Oncology was previously published as Nature Clinical Practice Oncology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.